Human GM-CSF Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB215
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Mouse
Applications
Validated:
Western Blot, Neutralization, Immunocytochemistry
Cited:
Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Neutralization, Immunodepletion
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 3209
Product Specifications
Immunogen
E. coli-derived recombinant human GM-CSF
Ala18-Glu144
Accession # P04141
Ala18-Glu144
Accession # P04141
Specificity
Detects human GM-CSF in Western blots.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human GM-CSF Antibody
GMCSF in Human PBMCs.
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) was detected in human peripheral blood mononuclear cells (PBMCs) using Human GM-CSF Monoclonal Antibody (Catalog # MAB215) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.Cell Proliferation Induced by GM-CSF and Neutralization by Human GM-CSF Antibody.
Recombinant Human GM-CSF (Catalog # 215-GM) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human GM-CSF (0.1 ng/mL) is neutralized (green line) by increasing concentrations of Human GM-CSF Monoclonal Antibody (Catalog # MAB215). The ND50 is typically 0.075-0.45 µg/mL.Detection of GM-CSF by Flow Cytometry
TC-derived soluble factors promoted neutrophil survival. A. Neutrophils were cultured in a TC-CM or the control medium. At the indicated time points, live cells were evaluated by flow cytometry with FITC-conjugated annexin V and PI. Results were expressed as percentages of live cells (mean ± SEM of five independent experiments); ***p < 0.005; **p < 0.01; *p < 0.05. B. Representative flow cytometric panels of dot plots of PMNs cultured in a TC-CM or control medium and stained with FITC-conjugated annexin V and propidium iodide (PI) at 24 (upper panels) and 48 (lower panels) hours. C. The GM-CSF release by TPC1 and 8505c cells was evaluated by an ELISA in a TC-CM or in the control medium. Results were expressed as mean ± SEM of seven independent experiments; ****p < 0.001; ***p < 0.005. D-F. Neutrophil survival in a TPC1-derived (D-E) or 8505c-derived (F-G) conditioned medium was evaluated in the presence of an anti-GM-CSF blocking antibody or the relative isotype control (10 μg/ml). At 24 hours, live cells were stained with FITC-conjugated annexin V and PI and analyzed by flow cytometry. Figs E and G illustrate representative flow cytometric panels of one out of five independent experiments. The results were expressed as mean ± SEM of five independent experiments; **p < 0.01; *p < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29953504), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human GM-CSF Antibody
Application
Recommended Usage
Immunocytochemistry
8-25 µg/mL
Sample: Immersion fixed human peripheral blood mononuclear cells
Sample: Immersion fixed human peripheral blood mononuclear cells
Western Blot
1 µg/mL
Sample: Recombinant Human GM-CSF (Catalog # 215-GM)
under non-reducing conditions only
Sample: Recombinant Human GM-CSF (Catalog # 215-GM)
under non-reducing conditions only
Neutralization
Measured by its ability to neutralize GM‑CSF-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.075-0.45 µg/mL in the presence of 0.1 ng/mL Recombinant Human GM‑CSF.
Reviewed Applications
Read 2 reviews rated 4.5 using MAB215 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: GM-CSF
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is a growth factor produced by a variety of lymphoid cells. It binds to receptor heterodimers consisting of a GM-CSF-specific alpha chain and the common beta chain that is shared by the high-affinity receptors for IL-3 and IL-5.
Long Name
Granulocyte Macrophage Growth Factor
Alternate Names
CSF-2, CSF2, GMCSF, Molgramostim, Sargramostim
Entrez Gene IDs
Gene Symbol
CSF2
UniProt
Additional GM-CSF Products
Product Documents for Human GM-CSF Antibody
Product Specific Notices for Human GM-CSF Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...